Linear IgA bullous dermatosis following Oxford AstraZeneca COVID‐19 vaccine
F. Hali, A. Kerouach, Hind Alatawna, S. Chiheb, H. Lakhdar
Abstract
A case of linear IgA bullous dermatosis developing 3 days after the second dose of Oxford AstraZeneca COVID-19 vaccine in an adult patient, suggesting a possible causal association. It is worth keeping in mind that COVID-19 vaccination could induce immune-mediated bullous disease in susceptible people.
Topics & Concepts
VenereologyMedicineUniversity hospitalCoronavirus disease 2019 (COVID-19)DermatologyLibrary scienceFamily medicinePathologyComputer scienceDiseaseInfectious disease (medical specialty)Autoimmune Bullous Skin DiseasesUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and Angioedema